On Thursday, November 23, 2017, AniCell Biotech launched its AniCell D product line of temperature independent products at the American Association of Equine Practitioners Annual Conference in San Antonio, Texas.
In general, regenerative therapies are serviced-based and require invasive harvesting and up to a month to culture before they can be used to treat injured animals, according to AniCell Biotech. The AniCell D line mitigates this becoming the first implantable, amnion-derived regenerative products ever to be stored at ambient temperature and able to be reconstituted in the field for animals.
In 2015, AniCell Biotech became the first company in veterinary medicine to offer regenerative treatments using amnion, a noninvasive, nondamaging form of regenerative therapy which uses the natural materials collected from the birth of an animal—primarily horses and dogs. This material can be used for wound management of soft tissue injuries including superficial wounds, tendon and ligament injuries, bone fractures, ocular wounds and joint issues.
Prior to the launch of the AniCell D line, these products were only available in a cryogenic (frozen) format. The ability to have all natural, safe amniotic-based products available in a cost-effective, temperature independent format transforms the industry paradigm requiring surgical suites, expensive lab equipment, and training to work with regenerative products. AniCell can now not only be used by rural mobile veterinarians in the field, but can also be brought to developing nations with limited access to veterinary hospitals and labs.
“We are incredibly excited to be leading this new technology to the marketplace,” says Brandon Ames, AniCell’s president and CEO. “Initial acceptance has been overwhelming. Sales for November 2017 are up over 240 percent compared with November 2016, which just serves to reinforce how high the market demand is for these types of products. I am extremely proud of all the hard work by the team to bring these innovative products to market.”